Silexion Therapeutics (NASDAQ:SLXN) Issues Quarterly Earnings Results

Silexion Therapeutics (NASDAQ:SLXN) issued its earnings results on Tuesday. The company reported $19.32 earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.17) by $20.49, FiscalAI reports.

Silexion Therapeutics Stock Down 0.6%

Shares of NASDAQ:SLXN traded down $0.01 during trading on Tuesday, reaching $1.56. 6,230 shares of the stock traded hands, compared to its average volume of 36,404. The stock has a market cap of $4.88 million, a P/E ratio of -0.14 and a beta of -0.04. The company has a debt-to-equity ratio of 0.22, a quick ratio of 3.97 and a current ratio of 3.97. The stock has a 50-day moving average of $1.84 and a two-hundred day moving average of $2.87. Silexion Therapeutics has a 52-week low of $1.42 and a 52-week high of $22.36.

Analysts Set New Price Targets

A number of research analysts recently issued reports on SLXN shares. Zacks Research upgraded Silexion Therapeutics to a “hold” rating in a report on Tuesday, December 16th. Litchfield Hills Research began coverage on shares of Silexion Therapeutics in a research note on Monday, December 15th. They set a “buy” rating on the stock. Finally, Wall Street Zen cut shares of Silexion Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, December 20th. Two equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Silexion Therapeutics presently has a consensus rating of “Hold” and a consensus price target of $75.00.

Silexion Therapeutics Company Profile

Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor.